RSV vaccine, GSK and Canada
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...
With RSV season approachgin, there are more options for those most susceptible to RSV, including a new vaccine and updated ...
GlobalData on MSN3d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback